Corneal endothelial cell protection during phacoemulsification: low- versus high-molecular-weight sodium hyaluronate

J Cataract Refract Surg. 2002 Sep;28(9):1557-60. doi: 10.1016/s0886-3350(02)01540-7.

Abstract

Purpose: To compare the efficacy of low- and high-molecular-weight sodium hyaluronate in protecting corneal endothelial cells during phacoemulsification.

Setting: Miyata Eye Hospital, Miyakonojo, Miyazaki, Japan.

Methods: One hundred forty-nine eyes of 136 cataract patients were randomly assigned to have cataract surgery using sodium hyaluronate 1% with a low molecular weight (0.6 to 1.2 million d, Opegan) or sodium hyaluronate 1% with a high molecular weight (4 million d, Healon) during phacoemulsification. Each group was divided into 2 subgroups depending on the amount of ultrasound (% min) used during phacoemulsification, which was defined as the mean phacoemulsification energy (%) multiplied by phacoemulsification time (minutes). Corneal endothelial cell density was examined preoperatively and 3 months after surgery. The rate of cell loss was compared between the subgroups in the Opegan group and the Healon group.

Results: In the subgroups with ultrasound of 50% min or less, the mean rate of endothelial cell loss 3 months after surgery was 3.2% +/- 4.1% (SD) in the Opegan group and 5.9% +/- 5.3% in the Healon group (P =.0214). In the subgroups with ultrasound over 50% min, the mean rate of endothelial cell loss 3 months after surgery was 7.5% +/- 10.6% in the Opegan group and 14.8 +/- 9.0% in the Healon group (P =.0029).

Conclusions: The results suggest that Opegan is more effective than Healon in protecting corneal endothelial cells during phacoemulsification regardless of the amount of ultrasound energy used.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Endothelium, Corneal / drug effects*
  • Endothelium, Corneal / pathology
  • Humans
  • Hyaluronic Acid / chemistry*
  • Hyaluronic Acid / therapeutic use*
  • Intraocular Pressure / drug effects
  • Middle Aged
  • Molecular Weight
  • Phacoemulsification* / methods
  • Ultrasonic Therapy

Substances

  • Hyaluronic Acid